References
- 1. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am. 1997; 24(2): 235-258. 2 D’Hooghe TM, Debrock S, Hill JA, Meuleman C. Endometriosis and subfertility: Is the relationship resolved? Semin Reprod Med 2003; 21(2): 243-254.
- 3. Vinatier D, Orazi G, Cosson M, Dufour P. Theories of endometriosis. Eur J Obstet Gynecol Reprod Biol. 2001; 96(1): 21-34.
- 4. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update. 2000; 6(1): 45-55.
- 5. Grothey A, Ellis LM. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J. 2008; 14(3):170-177.
- 6. Selvakumaran M, Yao KS, Feldman MD, O’Dwyer PJ. Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol. 2008; 75(3): 627-638.
- 7. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998; 394(6692): 485-490.
- 8. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 1999; 59(21): 5412-5416.
- 9. Gebel HM, Braun DP, Tambur A, Frame D, Rana N, Dmowski WP. Spontaneous apoptosis of endometrial tissue is impaired in women with endometriosis. Fertil Steril. 1998; 69(6): 1042-1047.
- 10. Safaeian L, Abed A, Vaseghi G. The role of Bcl-2 family proteins in pulmonary fibrosis. Eur J Pharmacol. 2014. pii: S0014-2999(14)00566-4. doi: 10.1016/j.ejphar. 2014.07.029.
- 11. Tesone M, Bilotas M, Barañao RI, Meresman G. The role of GnRH analogues in endometriosisassociated apoptosis and angiogenesis. Gynecol Obstet Invest. 2008; 66(Suppl 1): 10-18.
- 12. Vernon MW, Wilson EA. Studies on the surgical induction of endometriosis in the rat. Fertil Steril. 1985; 44(5): 684-694.
- 13. Linsky CB, Diamond MP, Cunningham T, Constantine B, De-Cherney AH, diZerega GS. Adhesion reduction in a rabbit uterine horn model using an absorbable barrier TC-7. J Reprod Med. 1987; 32(1): 17-20.
- 14. Keenan JA, Williams-Boyce PK, Massey PJ, Chen TT, Caudle MR, Bukovsky A. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril. 1999; 72(1): 135-141.
- 15. Crosignani P, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: An update for clinicians. Hum Reprod Update. 2006; 12(2): 179-189.
- 16. Matsuzaki S, Canis M, Murakami T, Dechelotte P, Bruhat MA, Okamura K. Immunohistochemical analysis of the role of angiogenic status in the vasculature of peritoneal endometriosis. Fertil Steril. 2001; 76(4): 712-716.
- 17. Mihalyi A, Simsa P, Mutinda KC, Meuleman C, Mwenda JM, D’Hooghe TM. Emerging drugs in endometriosis. Expert Opin Emerg Drugs. 2006; 11(3): 503-524.
- 18. Rice VM. Conventional medical therapies for endometriosis. Ann N Y Acad Sci. 2002; 955: 343-352.
- 19. Child TJ, Tan SL. Endometriosis: Aetiology, pathogenesis and treatment. Drugs. 2001; 61(12): 1735-1750.
- 20. Groothuis PG, Nap AW, Winterhager E, Grümmer R. Vascular development in endometriosis. Angiogenesis. 2005; 8(2): 147-156.
- 21. Donnez J, Smoes P, Gillerot S, Casanas-Roux F, Nisolle M. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod. 1998; 13(6): 1686-1690.
- 22. Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann N Y Acad Sci. 2002; 955: 89-100.
- 23. Nisolle M, Casanas-Roux F, Anaf V, Mine JM, Donnez J. Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril. 1993; 59(3):681-684.
- 24. Matsuzaki S, Canis M, Murakami T, Dechelotte P, Bruhat MA, Okamura K. Immunohistochemical analysis of the role of angiogenic status in the vasculature of peritoneal endometriosis. Fertil Steril. 2001; 76(4):712-716.
- 25. Hull ML, Charnock-Jones DS, Chan CL, Bruner- Tran KL, Osteen KG, Tom BD, et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab. 2003; 88(6): 2889-2899.
- 26. Dabrosin C, Gyorffy S, Margetts P, Ross C, Gauldie J. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am J Pathol. 2002; 161(3): 909-918.
- 27. Nap AW, Griffioen AW, Dunselman GA, Bouma- Ter Steege JC, Thijssen VL, Evers JL, et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab. 2004; 89(3): 1089-1095.
- 28. Becker CM, Sampson DA, Rupnick MA, Rohan RM, Efstathiou JA, Short SM, et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril. 2005; 84(Suppl 2): 1144-1155.
- 29. Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P, Menger MD. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod. 2006; 21(1): 262-268.
- 30. Novella-Maestre E, Carda C, Noguera I, Ruiz- Saurí A, García-Velasco JA, Simón C, et al. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod. 2009; 24(5): 1025-1035.
- 31. Ricci AG, Olivares CN, Bilotas MA, Meresman GF, Barañao RI. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis. Reprod Sci. 2011; 18(7): 614-622.
- 32. Meresman GF, Bilotas MA, Lombardi E, Tesone M, Sueldo C, Baranao R. Effect of GnRH analogues on apoptosis and release of interleukin-1β and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis. Hum Reprod. 2003; 18(9): 1767-1771.
- 33. Bilotas M, Barañao RI, Buquet R, Sueldo C, Tesone M, Meresman GF. Effect of GnRH analogues on apoptosis and expression of Bcl-2, Bax, Fas and FasL proteins in endometrial epithelial cell cultures from patients with endometriosis and controls. Hum Reprod. 2007; 22(3): 644-653.
- 34. Meresman GF, Bilotas M, Buquet RA, Barañao RI, Sueldo C, Tesone M. Gonadotropin-releasing hormone agonist induces apoptosis and reduces cell proliferation in eutopic endometrial cultures from women with endometriosis. Fertil Steril. 2003; 80(2): 702-707.
- 35. Imai A, Takagi A, Tamaya T. Gonadotropin-releasing hormone analog repairs reduced endometrial cell apoptosis in endometriosis in vitro. Am J Obstet Gynecol. 2000; 182(5): 1142-1146.
- 36. Khan KN, Kitajima M, Hiraki K, Fujishita A, Sekine I, Ishimaru T, et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod. 2010; 25(3): 642-653.
- 37. Moraloğlu O, Işik H, Kiliç S, Sahin U, Caydere M, Ustün H, et al. Effect of bevacizumab on postoperative adhesion formation in a rat uterine horn adhesion model and the correlation with vascular endothelial growth factor and Ki-67 immunopositivity. Fertil Steril. 2011; 95(8): 2638-2641.
- 38. Shord SS, Bressler LR, Tierney LA, Cuellar S, George A. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm. 2009; 66(11): 999-101.